Exc h-f-nk-sp b9+marg 2.1-3
CPT 11423 covers the surgical removal of a benign (non-cancerous) skin growth between 2.1 and 3.0 centimeters in diameter from the head, face, neck, hands, feet, or genitals, including margins to ensure complete removal.
This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.
RVU breakdown
Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High
NCCI bundling edits
Loading bundling edits…
Billing tips
Measure the lesion diameter at its greatest clinical dimension before excision and document precisely in the operative note. If the lesion measures exactly 2.0 cm, use 11422 instead; if 3.1 cm or greater, use 11424.
Impact: Incorrect size selection costs $32-48 per claim; 11422 pays $168.91 vs 11423 at $200.87 vs 11424 at $248.42
Verify anatomic site qualifies for the H-F-Nk-Sp series (head, face, neck, scalp, hands, feet, genitalia). Lesions on trunk or extremities require 11400-series codes with significantly lower reimbursement.
Impact: Incorrect anatomic series selection results in payment difference of approximately $70-90; 11403 (trunk 2.1-3.0cm) pays only $130.54
When performing multiple excisions, list the largest or most complex excision first without modifier 51, then append modifier 51 to all subsequent excisions to maximize reimbursement under multiple procedure rules.
Impact: Proper sequencing maximizes payment; incorrect ordering can reduce total reimbursement by $50-100 for multiple excision sessions
Document whether the procedure was performed in a facility or non-facility setting accurately on the claim. Non-facility settings reimburse $45.28 more per procedure due to higher practice expense.
Impact: Place of service errors result in $45.28 underpayment or overpayment per claim and may trigger audits
Include pathology documentation confirming benign diagnosis. If pathology reveals malignancy, the excision may need to be recoded to malignant lesion series (11640-11646) with different reimbursement and global periods.
Impact: Failure to recode after malignant pathology results in underpayment of $80-150 and exposes practice to audit risk for incorrect coding
Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.
Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.
Help build the field knowledge
MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.